Several risk factors may help predict the chances of competing mortality -- or death from non-cancer causes -- in patients with head and neck cancer, according to research published online Nov. 23 in the Journal of Clinical Oncology.
A cell biologist who has devoted much of his career to understanding the process of cancer argues that the skin may hold the key to predicting cancer risk of the colon, breast and more.
According to preliminary data, administration of curcumin diminishes the severity of radiation dermatitis, a common adverse event in cancer patients who are receiving radiation therapy.
New molecular entity: Pralatrexate injection (Folotyn) was approved on September 24, 2009, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Practice Tools
